Jin Medical International Ltd.

What they do

The company, through its VIE Changzhou Zhongjin and its subsidiaries, designs, manufactures and sells orthopedic and surgical appliances and supplies. It operates primarily in mainland China, with principal executive offices in Changzhou, Jiangsu Province. The company is controlled through a series of contractual arrangements (VIE Agreements) with the WFOE and Changzhou Zhongjin's shareholders.

Revenue drivers

• Orthopedic implants and instruments — Core product line; likely the largest revenue contributor, but specific split not disclosed in the provided excerpts.
• Surgical supplies and disposables — Additional product category; size relative to total revenue not quantified in the excerpts.
• Domestic PRC sales — Sales are primarily in mainland China; no export revenue figures are provided.
• Contract manufacturing / VIE service fees — The VIE agreements include exclusive business cooperation and service arrangements, which may generate service fees from the WFOE to the VIE, but financial details are not disclosed.

Recent performance

For fiscal year 2025 (ended September 30, 2025), revenue declined to $20.7M from $23.5M in 2024, a drop of approximately 12%. Net income fell sharply to $1.2M from $3.7M, a decline of about 68%. Diluted EPS was $0.01 versus $0.02 in the prior year. Operating cash flow improved to $2.9M from a negative $1.2M in 2024. Balance sheet at September 30, 2025 showed total assets of $53.4M, total liabilities of $23.8M, shareholder equity of $29.6M, and cash of $7.5M.

Strategy

The company's strategy centers on operating and expanding its orthopedic and surgical appliance business in China, as described in the annual report. It maintains a VIE structure to control its PRC operating entities. The company emphasizes compliance with PRC laws and regulations and has established a code of ethics and insider trading policies. It also highlights corporate governance measures, including an audit committee financial expert. Specific growth initiatives, such as new product development or market expansion, are not detailed in the provided excerpts.

Risks

• VIE structure risk — The company's operations depend on contractual arrangements with Changzhou Zhongjin; if PRC regulators determine these arrangements are invalid, the company could lose control of its operating business.
• Regulatory risk in PRC — Changes in PRC laws or enforcement regarding VIE structures, foreign investment, or the medical device industry could adversely affect operations.
• Revenue concentration in China — The company's revenue is concentrated in mainland China, making it vulnerable to domestic economic, regulatory, or competitive factors.
• Profitability volatility — Net income declined 68% in fiscal 2025 despite relatively stable revenue, indicating potential cost pressures or operational challenges.

Outlook

The excerpts do not include a forward-looking outlook section from management; the MD&A section referenced in the filing table of contents is not included in the provided material. As a result, no specific management guidance or projections are available.